

The Preclinical Alzheimer Cognitive Composite

JAMA Neurology

71, 961

DOI: [10.1001/jamaneurol.2014.803](https://doi.org/10.1001/jamaneurol.2014.803)

Citation Report

#	ARTICLE	IF	CITATIONS
1	A Rehabilomics framework for personalized and translational rehabilitation research and care for individuals with disabilities: Perspectives and considerations for spinal cord injury. Journal of Spinal Cord Medicine, 2014, 37, 493-502.	1.4	15
2	Subjective and objective cognitive decline at the pre-dementia stage of Alzheimer's disease. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 3-7.	3.2	116
3	Synergistic Effect of β -Amyloid and Neurodegeneration on Cognitive Decline in Clinically Normal Individuals. JAMA Neurology, 2014, 71, 1379.	9.0	273
4	Secondary Prevention Trials in Alzheimer Disease. JAMA Neurology, 2014, 71, 947.	9.0	20
5	The Evolution of Preclinical Alzheimer's Disease: Implications for Prevention Trials. Neuron, 2014, 84, 608-622.	8.1	568
6	Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2015, 2, 534-547.	3.7	32
7	Alzheimer's disease. Nature Reviews Disease Primers, 2015, 1, 15056.	30.5	1,210
8	Efficacy and Safety of MMFS-01, a Synapse Density Enhancer, for Treating Cognitive Impairment in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Alzheimer's Disease, 2016, 49, 971-990.	2.6	47
9	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2015, 48, S171-S191.	2.6	34
10	Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study. Journal of Alzheimer's Disease, 2015, 46, 1079-1089.	2.6	28
11	Optimal composite scores for longitudinal clinical trials under the linear mixed effects model. Pharmaceutical Statistics, 2015, 14, 418-426.	1.3	24
12	Cerebrospinal Fluid A β Levels: When Physiological Become Pathological State. CNS Neuroscience and Therapeutics, 2015, 21, 921-925.	3.9	41
13	Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. Nature Neuroscience, 2015, 18, 800-806.	14.8	582
14	Revolutionizing Alzheimer's disease and clinical trials through biomarkers. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 412-419.	2.4	80
15	Brain structure and function as mediators of the effects of amyloid on memory. Neurology, 2015, 84, 1136-1144.	1.1	44
16	Tracking Early Decline in Cognitive Function in Older Individuals at Risk for Alzheimer Disease Dementia. JAMA Neurology, 2015, 72, 446.	9.0	142
17	Treatment of Mild Cognitive Impairment. Current Treatment Options in Neurology, 2015, 17, 372.	1.8	13
18	Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans. Alzheimer's and Dementia, 2015, 11, 734-739.	0.8	80

#	ARTICLE	IF	CITATIONS
19	Neural and behavioral substrates of disorientation in mild cognitive impairment and Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2015, 1, 37-45.	3.7	23
20	Prevention Studies in Alzheimer's Disease: Progress Towards the Development of New Therapeutics. <i>CNS Drugs</i> , 2015, 29, 519-528.	5.9	7
21	The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding. <i>Alzheimer's and Dementia</i> , 2015, 11, 823-831.	0.8	60
22	Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans. <i>Alzheimer's and Dementia</i> , 2015, 11, 792-814.	0.8	241
23	Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. <i>Lancet Neurology</i> , The, 2015, 14, 926-944.	10.2	227
24	Memory, executive, and multidomain subtle cognitive impairment. <i>Neurology</i> , 2015, 85, 144-153.	1.1	42
25	Age, Sex, and APOE ϵ 4 Effects on Memory, Brain Structure, and β -Amyloid Across the Adult Life Span. <i>JAMA Neurology</i> , 2015, 72, 511.	9.0	305
26	"Boomerang Neuropathology" of Late-Onset Alzheimer's Disease is Shrouded in Harmful "BDDS": Breathing, Diet, Drinking, and Sleep During Aging. <i>Neurotoxicity Research</i> , 2015, 28, 55-93.	2.7	11
27	Predicting Reduction of Cerebrospinal Fluid β -Amyloid 42 in Cognitively Healthy Controls. <i>JAMA Neurology</i> , 2015, 72, 554.	9.0	42
28	Update on Disease-Modifying/Preventive Therapies in Alzheimer's Disease. <i>Current Geriatrics Reports</i> , 2015, 4, 312-317.	1.1	10
29	Conventional and robust norming in identifying preclinical dementia. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2015, 37, 1098-1106.	1.3	12
30	Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 83-105.	2.8	64
31	Allocentric Spatial Memory Testing Predicts Conversion from Mild Cognitive Impairment to Dementia: An Initial Proof-of-Concept Study. <i>Frontiers in Neurology</i> , 2016, 7, 215.	2.4	30
32	Prevention Trials in Alzheimer's Disease: Current Status and Future Perspectives. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 927-945.	2.6	22
33	Redefining Amnesic Mild Cognitive Impairment as an Early Form of Alzheimer's Disease Based on Assessment of Memory Systems. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 705-712.	2.6	3
34	Early detection of cryptic memory and glucose uptake deficits in pre-pathological APP mice. <i>Nature Communications</i> , 2016, 7, 11761.	12.8	12
35	Mild Cognitive Impairment in Late Middle Age in the Wisconsin Registry for Alzheimer's Prevention Study: Prevalence and Characteristics Using Robust and Standard Neuropsychological Normative Data. <i>Archives of Clinical Neuropsychology</i> , 2016, 31, 675-688.	0.5	48
36	Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change. <i>JAMA Neurology</i> , 2016, 73, 698.	9.0	94

#	ARTICLE	IF	CITATIONS
37	Glycemic control, cognitive function, and family support among middle-aged and older Hispanics with diabetes: The Hispanic Community Health Study/Study of Latinos. <i>Diabetes Research and Clinical Practice</i> , 2016, 117, 64-73.	2.8	19
38	Cognitive and functional changes associated with A β pathology and the progression to mild cognitive impairment. <i>Neurobiology of Aging</i> , 2016, 48, 172-181.	3.1	28
39	Diagnostic de la maladie d'Alzheimer: apport de l'imagerie au florbétapir et autres radiopharmaceutiques de la plaque amyloïde. <i>Medecine Nucleaire</i> , 2016, 40, 364-381.	0.2	2
40	Emerging drugs to reduce abnormal β -amyloid protein in Alzheimer's disease patients. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 377-391.	2.4	54
41	Episodic memory of odors stratifies Alzheimer biomarkers in normal elderly. <i>Annals of Neurology</i> , 2016, 80, 846-857.	5.3	36
42	Incidence and impact of subclinical epileptiform activity in Alzheimer's disease. <i>Annals of Neurology</i> , 2016, 80, 858-870.	5.3	373
43	Longitudinal Positron Emission Tomography in Preventive Alzheimer's Disease Drug Trials, Critical Barriers from Imaging Science Perspective. <i>Brain Pathology</i> , 2016, 26, 664-671.	4.1	5
44	Physical Activity and Cognitive Function in Middle-Aged and Older Adults. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1515-1524.	3.0	45
45	Evaluating the clinical relevance of a cognitive composite outcome measure: An analysis of 1414 participants from the 5-year GuidAge Alzheimer's prevention trial. <i>Alzheimer's and Dementia</i> , 2016, 12, 1216-1225.	0.8	23
46	Which Cognitive Domains are Improved by Treatment with Vortioxetine?. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyw054.	2.1	46
47	Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals. <i>JAMA Neurology</i> , 2016, 73, 1185.	9.0	52
48	<i>BDNF</i> Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. <i>Brain</i> , 2016, 139, 2766-2777.	7.6	70
49	Drug development in Alzheimer's disease: the path to 2025. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 39.	6.2	323
50	Loneliness as a Marker of Brain Amyloid Burden and Preclinical Alzheimer Disease. <i>JAMA Psychiatry</i> , 2016, 73, 1237.	11.0	7
51	Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 2, 19-26.	2.4	72
52	Quantitative MRI to understand Alzheimer's disease pathophysiology. <i>Current Opinion in Neurology</i> , 2016, 29, 437-444.	3.6	37
53	Two-stage screening for early dementia in primary care. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2016, 38, 1038-1049.	1.3	12
54	Intraneuronal Amyloid Beta Accumulation Disrupts Hippocampal CRTC1-Dependent Gene Expression and Cognitive Function in a Rat Model of Alzheimer Disease. <i>Cerebral Cortex</i> , 2016, 27, 1501-1511.	2.9	39

#	ARTICLE	IF	CITATIONS
55	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016, 12, 292-323.	0.8	1,318
56	Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit. <i>Alzheimer's and Dementia</i> , 2016, 12, 614-622.	0.8	42
57	Apolipoprotein E (APOE) ϵ 4 and episodic memory decline in Alzheimer's disease: A review. <i>Ageing Research Reviews</i> , 2016, 27, 15-22.	10.9	70
58	The 5-HT _{2A} serotonin receptor in executive function: Implications for neuropsychiatric and neurodegenerative diseases. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 64, 63-82.	6.1	62
59	Beta-amyloid and cognitive decline in late middle age: Findings from the Wisconsin Registry for Alzheimer's Prevention study. <i>Alzheimer's and Dementia</i> , 2016, 12, 805-814.	0.8	59
60	Corticotropin-releasing factor receptor ₁ antagonism mitigates beta amyloid pathology and cognitive and synaptic deficits in a mouse model of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 527-537.	0.8	45
61	CAP ₁ advancing the evaluation of preclinical Alzheimer disease treatments. <i>Nature Reviews Neurology</i> , 2016, 12, 56-61.	10.1	80
62	Risk of dementia and death in the long-term follow-up of the Pittsburgh Cardiovascular Health Study's "Cognition Study". <i>Alzheimer's and Dementia</i> , 2016, 12, 170-183.	0.8	33
63	Subtle visuomotor difficulties in preclinical Alzheimer's disease. <i>Journal of Neuropsychology</i> , 2017, 11, 56-73.	1.4	13
64	Reduced global brain metabolism but maintained vascular function in amnesic mild cognitive impairment. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 1508-1516.	4.3	41
65	Design of pilot studies to inform the construction of composite outcome measures. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 213-218.	3.7	8
66	Face-Name Associative Recognition Deficits in Subjective Cognitive Decline and Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 1185-1196.	2.6	37
67	A composite measure of cognitive and functional progression in Alzheimer's disease: Design of the Capturing Changes in Cognition study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 130-138.	3.7	26
68	Cued memory decline in biomarker-defined preclinical Alzheimer disease. <i>Neurology</i> , 2017, 88, 1431-1438.	1.1	46
69	Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β . <i>Alzheimer's and Dementia</i> , 2017, 13, 1004-1012.	0.8	139
70	Geniposide attenuates the level of A β 1-42 via enhancing leptin signaling in cellular and APP/PS1 transgenic mice. <i>Archives of Pharmacol Research</i> , 2017, 40, 571-578.	6.3	22
71	Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept. <i>Alzheimer's and Dementia</i> , 2017, 13, 454-467.	0.8	58
72	Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease. <i>Neurobiology of Aging</i> , 2017, 56, 25-32.	3.1	57

#	ARTICLE	IF	CITATIONS
73	Detectable Neuropsychological Differences in Early Preclinical Alzheimer's Disease: A Meta-Analysis. <i>Neuropsychology Review</i> , 2017, 27, 305-325.	4.9	76
74	Accelerating drug development for Alzheimer's disease through the use of data standards. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 273-283.	3.7	10
75	The neurology of ageing: what is normal?. <i>Practical Neurology</i> , 2017, 17, 172-182.	1.1	32
76	Prolonged changes in amyloid- β metabolism after a severe traumatic brain injury. <i>NeuroReport</i> , 2017, 28, 250-252.	1.2	6
77	Imaging plus X: multimodal models of neurodegenerative disease. <i>Current Opinion in Neurology</i> , 2017, 30, 371-379.	3.6	75
78	Functional network integrity presages cognitive decline in preclinical Alzheimer disease. <i>Neurology</i> , 2017, 89, 29-37.	1.1	106
79	Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2305.	7.4	311
80	Brain Amyloid Pathology and Cognitive Function. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2285.	7.4	15
81	Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. <i>Alzheimer's and Dementia</i> , 2017, 13, e1-e85.	0.8	213
82	Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2017, 16, 377-389.	10.2	576
83	Cross-validation of optimized composites for preclinical Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 123-129.	3.7	18
84	The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. <i>Alzheimer's and Dementia</i> , 2017, 13, 561-571.	0.8	266
85	Alzheimer's disease prevention: from risk factors to early intervention. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 71.	6.2	424
86	Impact of Amyloid Burden on Regional Functional Synchronization in the Cognitively Normal Older Adults. <i>Scientific Reports</i> , 2017, 7, 14690.	3.3	22
87	Potential implications of practice effects in Alzheimer's disease prevention trials. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 531-535.	3.7	14
88	Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1119-1128.	2.6	27
89	Statistical considerations for assessing cognition and neuropathology associations in preclinical Alzheimer's disease. <i>Biostatistics and Epidemiology</i> , 2017, 1, 92-104.	0.4	4
90	Associations between white matter hyperintensities and cognitive decline over three years in non-dementia older adults with memory complaints. <i>Journal of the Neurological Sciences</i> , 2017, 379, 266-270.	0.6	13

#	ARTICLE	IF	CITATIONS
91	BACE1 inhibition by microdose lithium formulation NP03 rescues memory loss and early stage amyloid neuropathology. Translational Psychiatry, 2017, 7, e1190-e1190.	4.8	33
92	The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 513-523.	3.7	17
93	Study protocol: Insight 46 – a neuroscience sub-study of the MRC National Survey of Health and Development. BMC Neurology, 2017, 17, 75.	1.8	64
94	Detecting cognitive changes in preclinical Alzheimer's disease: A review of its feasibility. Alzheimer's and Dementia, 2017, 13, 468-492.	0.8	131
95	Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 668-677.	3.7	160
96	Linear combinations of multiple outcome measures to improve the power of efficacy analysis—Application to clinical trials on early-stage Alzheimer's disease. Biostatistics and Epidemiology, 2017, 1, 36-58.	0.4	5
98	Cognitive and Functional Considerations in Alzheimer's Disease Diagnosis. , 2017, , 17-26.		0
99	TRAJECTORY OF THE MAPT-PACC-PRECLINICAL ALZHEIMER COGNITIVE COMPOSITE IN THE PLACEBO GROUP OF A RANDOMIZED CONTROL TRIAL: RESULTS FROM THE MAPT STUDY: LESSONS FOR FURTHER TRIALS. Journal of prevention of Alzheimer's disease, The, 2018, 5, 1-5.	2.7	10
100	Excessive Sleepiness and Longer Nighttime in Bed Increase the Risk of Cognitive Decline in Frail Elderly Subjects: The MAPT-Sleep Study. Frontiers in Aging Neuroscience, 2017, 9, 312.	3.4	26
101	Subjective and objective cognitive function among older adults with a history of traumatic brain injury: A population-based cohort study. PLoS Medicine, 2017, 14, e1002246.	8.4	37
102	On the path to 2025: understanding the Alzheimer's disease continuum. Alzheimer's Research and Therapy, 2017, 9, 60.	6.2	316
103	Study partners should be required in preclinical Alzheimer's disease trials. Alzheimer's Research and Therapy, 2017, 9, 93.	6.2	22
104	Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward. Current Alzheimer Research, 2017, 14, 426-440.	1.4	68
105	The past, present, and future of disease-modifying therapies for Alzheimer's disease. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 2017, 93, 757-771.	3.8	31
106	Longitudinal Modeling of Functional Decline Associated with Pathologic Alzheimer's Disease in Older Persons without Cognitive Impairment. Journal of Alzheimer's Disease, 2018, 62, 855-865.	2.6	5
107	Cognitive and neuroimaging features and brain β -amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. Lancet Neurology, The, 2018, 17, 335-346.	10.2	161
108	Measuring cognition and function in the preclinical stage of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 64-75.	3.7	87
109	Cognitive gene risk profile for the prediction of cognitive decline in presymptomatic Alzheimer's disease. Personalized Medicine in Psychiatry, 2018, 7-8, 14-20.	0.1	13

#	ARTICLE	IF	CITATIONS
110	Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S3-S22.	2.6	108
111	Regulatory-accepted drug development tools are needed to accelerate innovative CNS disease treatments. <i>Biochemical Pharmacology</i> , 2018, 151, 291-306.	4.4	27
112	Circadian Rhythms Disturbances in Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2018, 32, 162-171.	1.3	14
113	Mobile and pervasive computing technologies and the future of Alzheimer's clinical trials. <i>Npj Digital Medicine</i> , 2018, 1, 1.	10.9	197
114	Transcranial magnetic stimulation of the precuneus enhances memory and neural activity in prodromal Alzheimer's disease. <i>NeuroImage</i> , 2018, 169, 302-311.	4.2	234
115	Effects of APOE ϵ 4 allele load on brain morphology in a cohort of middle-aged healthy individuals with enriched genetic risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 902-912.	0.8	98
116	Fluid Biomarkers in Alzheimer's Disease and Frontotemporal Dementia. , 2018, , 221-252.		1
117	Temporal unfolding of declining episodic memory on the Free and Cued Selective Reminding Test in the predementia phase of Alzheimer's disease: Implications for clinical trials. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 161-171.	2.4	36
118	The importance of endpoint selection: How effective does a drug need to be for success in a clinical trial of a possible Alzheimer's disease treatment?. <i>European Journal of Epidemiology</i> , 2018, 33, 635-644.	5.7	19
119	Novel Cognitive Paradigms for the Detection of Memory Impairment in Preclinical Alzheimer's Disease. <i>Assessment</i> , 2018, 25, 348-359.	3.1	85
120	Understanding heterogeneity in older adults: Latent growth curve modeling of cognitive functioning. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2018, 40, 292-302.	1.3	11
121	Physical activity domains and cognitive function over three years in older adults with subjective memory complaints: Secondary analysis from the MAPT trial. <i>Journal of Science and Medicine in Sport</i> , 2018, 21, 52-57.	1.3	10
122	The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 25-35.	3.1	34
123	Brain and cognitive correlates of subjective cognitive decline-plus features in a population-based cohort. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 123.	6.2	73
124	WHO GUIDELINES ON COMMUNITY-LEVEL INTERVENTIONS TO MANAGE DECLINES IN INTRINSIC CAPACITY: THE ROAD TO PREVENTION COGNITIVE DECLINE IN OLDER AGE?. <i>Journal of prevention of Alzheimer's disease</i> , The, 2018, 5, 1-3.	2.7	22
125	6 .Diagnostische Methoden. , 2018, , 187-352.		0
126	Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1193-1211.	2.6	27
127	Operationalized definition of older adults with high cognitive performance. <i>Dementia E Neuropsychologia</i> , 2018, 12, 221-227.	0.8	23

#	ARTICLE	IF	CITATIONS
128	A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 423.	3.4	16
129	Uncovering Biologically Coherent Peripheral Signatures of Health and Risk for Alzheimer's Disease in the Aging Brain. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 390.	3.4	39
130	Speech Analysis by Natural Language Processing Techniques: A Possible Tool for Very Early Detection of Cognitive Decline?. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 369.	3.4	91
131	Clinical and cognitive characteristics of preclinical Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 645-651.	3.7	16
132	Current Knowledge and Clinical Application of Brain Imaging in Alzheimer's Disease. <i>Journal of Korean Neuropsychiatric Association</i> , 2018, 57, 12.	0.5	2
133	Amyloid-associated increases in longitudinal report of subjective cognitive complaints. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 444-449.	3.7	51
134	A randomized controlled trial of combined executive function and memory training on the cognitive and noncognitive function of individuals with mild cognitive impairment: Study rationale and protocol design. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 556-564.	3.7	12
135	Cognitive composite score association with Alzheimer's disease plaque and tangle pathology. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 90.	6.2	23
136	Sex, amyloid, and <i>APOE</i> ϵ 4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts. <i>Alzheimer's and Dementia</i> , 2018, 14, 1193-1203.	0.8	169
137	Neural correlates of episodic memory in the Memento cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 224-233.	3.7	23
138	Interactive Associations of Vascular Risk and β -Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals. <i>JAMA Neurology</i> , 2018, 75, 1124.	9.0	165
139	Amyloid Accumulation and Cognitive Decline in Clinically Normal Older Individuals: Implications for Aging and Early Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S633-S646.	2.6	52
140	A novel cognitive disease progression model for clinical trials in autosomal dominant Alzheimer's disease. <i>Statistics in Medicine</i> , 2018, 37, 3047-3055.	1.6	31
141	Episodic memory and executive functions in cognitively healthy individuals display distinct neuroanatomical correlates which are differentially modulated by aging. <i>Human Brain Mapping</i> , 2018, 39, 4565-4579.	3.6	32
142	Recent advancements toward therapeutic vaccines against Alzheimer's disease. <i>Expert Review of Vaccines</i> , 2018, 17, 707-721.	4.4	46
143	TOMMORROW neuropsychological battery: German language validation and normative study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 314-323.	3.7	9
144	Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 61.	6.2	8
145	Is Computerized Working Memory Training Effective in Healthy Older Adults? Evidence from a Multi-Site, Randomized Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 931-949.	2.6	31

#	ARTICLE	IF	CITATIONS
146	Allocentric and Egocentric Spatial Processing in Middle-Aged Adults at High Risk of Late-Onset Alzheimer's Disease: The PREVENT Dementia Study. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 885-896.	2.6	37
147	Increased CAIDE dementia risk, cognition, CSF biomarkers, and vascular burden in healthy adults. <i>Neurology</i> , 2018, 91, e217-e226.	1.1	22
148	Stopping Cognitive Decline in Patients With Late-Life Depression: A New Front in the Fight Against Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2018, 26, 828-834.	1.2	5
149	Anticholinergic exposure and cognitive decline in older adults: effect of anticholinergic exposure definitions in a 3-year analysis of the multidomain Alzheimer preventive trial (MAPT) study. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 71-99.	2.4	18
150	Longitudinal Association of Depression Symptoms With Cognition and Cortical Amyloid Among Community-Dwelling Older Adults. <i>JAMA Network Open</i> , 2019, 2, e198964.	5.9	72
151	Assessing cost-effectiveness of early intervention in Alzheimer's disease: An open-source modeling framework. <i>Alzheimer's and Dementia</i> , 2019, 15, 1309-1321.	0.8	38
152	THE 2018 REVISED FDA GUIDANCE FOR EARLY ALZHEIMER'S DISEASE: ESTABLISHING THE MEANINGFULNESS OF TREATMENT EFFECTS. <i>Journal of prevention of Alzheimer's disease</i> , The, 2019, 6, 1-5.	2.7	18
153	Determining clinically meaningful decline in preclinical Alzheimer disease. <i>Neurology</i> , 2019, 93, e322-e333.	1.1	96
154	Associations of Physical Activity and β -Amyloid With Longitudinal Cognition and Neurodegeneration in Clinically Normal Older Adults. <i>JAMA Neurology</i> , 2019, 76, 1203.	9.0	97
155	The Assessment of Cognition in Translational Medicine: A Contrast Between the Approaches Used in Alzheimer's Disease and Major Depressive Disorder. <i>Handbook of Behavioral Neuroscience</i> , 2019, 29, 297-308.	0.7	4
156	The relative efficiency of time-to-onset progression and continuous measures of cognition in presymptomatic Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 308-318.	3.7	11
157	Translational Medicine Strategies in Alzheimer's Disease Drug Development. <i>Handbook of Behavioral Neuroscience</i> , 2019, , 349-362.	0.7	0
158	Subjective Cognitive Decline and Biomarkers of Preclinical Alzheimer's Disease. <i>Current Behavioral Neuroscience Reports</i> , 2019, 6, 219-226.	1.3	1
159	Cognition at age 70. <i>Neurology</i> , 2019, 93, e2144-e2156.	1.1	37
160	Biomarker-Based Signature of Alzheimer's Disease in Pre-MCI Individuals. <i>Brain Sciences</i> , 2019, 9, 213.	2.3	15
161	APPLICATION OF THE NIA-AA RESEARCH FRAMEWORK: TOWARDS A BIOLOGICAL DEFINITION OF ALZHEIMER'S DISEASE USING CEREBROSPINAL FLUID BIOMARKERS IN THE AIBL STUDY. <i>Journal of prevention of Alzheimer's disease</i> , The, 2019, 6, 1-8.	2.7	20
162	Association between anticholinergic (atropinic) drug exposure and cognitive function in longitudinal studies among individuals over 50 years old: a systematic review. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1631-1644.	1.9	19
163	Validation of a digitally delivered visual paired comparison task: reliability and convergent validity with established cognitive tests. <i>GeroScience</i> , 2019, 41, 441-454.	4.6	21

#	ARTICLE	IF	CITATIONS
164	Perspective: Clinical relevance of the dichotomous classification of Alzheimer's disease biomarkers: Should there be a "gray zone"? Alzheimer's and Dementia, 2019, 15, 1348-1356.	0.8	20
165	Associations of C-reactive protein and homocysteine concentrations with the impairment of intrinsic capacity domains over a 5-year follow-up among community-dwelling older adults at risk of cognitive decline (MAPT Study). Experimental Gerontology, 2019, 127, 110716.	2.8	39
166	Multidomain intervention and/or omega-3 in nondemented elderly subjects according to amyloid status. Alzheimer's and Dementia, 2019, 15, 1392-1401.	0.8	35
167	Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults. JAMA Neurology, 2019, 76, 542.	9.0	201
168	Klotho allele status is not associated with A β 2 and APOE ϵ 4-related cognitive decline in preclinical Alzheimer's disease. Neurobiology of Aging, 2019, 76, 162-165.	3.1	23
169	Timing of onset and rate of decline in learning and retention in the pre-dementia phase of Alzheimer's disease. Journal of the International Neuropsychological Society, 2019, 25, 699-705.	1.8	13
170	COMT val158met is not associated with A β 2-amyloid and APOE ϵ 4 related cognitive decline in cognitively normal older adults. IBRO Reports, 2019, 6, 147-152.	0.3	5
171	Neuropsychological Decline Improves Prediction of Dementia Beyond Alzheimer's Disease Biomarker and Mild Cognitive Impairment Diagnoses. Journal of Alzheimer's Disease, 2019, 69, 1171-1182.	2.6	19
172	Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort. Alzheimer's Research and Therapy, 2019, 11, 45.	6.2	19
173	Differential effects of neurodegeneration biomarkers on subclinical cognitive decline. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 129-138.	3.7	22
174	Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly. Cerebral Cortex, 2019, 29, 2173-2182.	2.9	39
175	An UNC5C Allele Predicts Cognitive Decline and Hippocampal Atrophy in Clinically Normal Older Adults. Journal of Alzheimer's Disease, 2019, 68, 1161-1170.	2.6	5
176	Rationale and methods for a multicenter clinical trial assessing exercise and intensive vascular risk reduction in preventing dementia (rrAD Study). Contemporary Clinical Trials, 2019, 79, 44-54.	1.8	15
177	Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer's Disease. New England Journal of Medicine, 2019, 380, 1483-1485.	27.0	149
178	Biomarker Matrix to Track Short Term Disease Progression in Amnesic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 69, 49-58.	2.6	8
179	Obstructive sleep apnea and longitudinal Alzheimer's disease biomarker changes. Sleep, 2019, 42, .	1.1	113
180	Measuring longitudinal cognition: Individual tests versus composites. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 74-84.	2.4	69
181	Sex-specific composite scales for longitudinal studies of incipient Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 508-514.	3.7	9

#	ARTICLE	IF	CITATIONS
182	Study partner types and prediction of cognitive performance: implications to preclinical Alzheimer's trials. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 92.	6.2	13
183	Consensus statement on the neurocognitive outcomes for early detection of mild cognitive impairment and Alzheimer dementia from the Chinese Neuropsychological Normative (CN-NORM) Project. <i>Journal of Global Health</i> , 2019, 9, 020320.	2.7	17
184	Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention. <i>CNS Drugs</i> , 2019, 33, 99-106.	5.9	33
185	A critical appraisal of amyloid- β -targeting therapies for Alzheimer's disease. <i>Nature Reviews Neurology</i> , 2019, 15, 73-88.	10.1	666
186	Cerebral Amyloid Angiopathy and Neuritic Plaque Pathology Correlate with Cognitive Decline in Elderly Non-Demented Individuals. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 411-422.	2.6	8
187	Biomarkers for Alzheimer Dementia in Diverse Racial and Ethnic Minorities—A Public Health Priority. <i>JAMA Neurology</i> , 2019, 76, 251.	9.0	37
188	Amyloid- β immunotherapy for alzheimer disease: Is it now a long shot?. <i>Annals of Neurology</i> , 2019, 85, 303-315.	5.3	126
189	Flexible Locally Weighted Penalized Regression With Applications on Prediction of Alzheimer's Disease Neuroimaging Initiative's Clinical Scores. <i>IEEE Transactions on Medical Imaging</i> , 2019, 38, 1398-1408.	8.9	7
190	Spatiotemporal Oscillatory Patterns During Working Memory Maintenance in Mild Cognitive Impairment and Subjective Cognitive Decline. <i>International Journal of Neural Systems</i> , 2020, 30, 1950019.	5.2	17
191	Setbacks and Opportunities in Disease-Modifying Therapies in Alzheimer Disease. <i>JAMA Psychiatry</i> , 2020, 77, 7.	11.0	5
192	Gold Nanoparticles Treatment Reverses Brain Damage in Alzheimer's Disease Model. <i>Molecular Neurobiology</i> , 2020, 57, 926-936.	4.0	80
193	Neuron-Derived Plasma Exosome Proteins after Remote Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2020, 37, 382-388.	3.4	47
194	Amyloid- β Positivity Predicts Cognitive Decline but Cognition Predicts Progression to Amyloid- β Positivity. <i>Biological Psychiatry</i> , 2020, 87, 819-828.	1.3	24
195	Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 8.	6.2	12
196	Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age. <i>Brain</i> , 2020, 143, 320-335.	7.6	100
197	Aligning Treatment Policy Estimands and Estimators—A Simulation Study in Alzheimer's Disease. <i>Statistics in Biopharmaceutical Research</i> , 2020, 12, 142-154.	0.8	12
198	Identification of Pre-Clinical Alzheimer's Disease in a Population of Elderly Cognitively Normal Participants. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 683-693.	2.6	0
199	Pragmatic Trials and Repurposed Drugs for Alzheimer Disease. <i>JAMA Neurology</i> , 2020, 77, 162.	9.0	3

#	ARTICLE	IF	CITATIONS
200	Temporal changes in the likelihood of dementia and MCI over 18 years in a population sample. <i>Neurology</i> , 2020, 94, e292-e298.	1.1	7
201	Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD. <i>Alzheimer's and Dementia</i> , 2020, 16, 552-560.	0.8	55
202	Influence of Comorbidity of Cerebrovascular Disease and Amyloid- β^2 on Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 897-907.	2.6	21
203	Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. <i>Brain</i> , 2020, 143, 3234-3241.	7.6	150
204	Association between cognitive quotient test score and hippocampal volume: a novel, rapid application-based screening tool. <i>Scientific Reports</i> , 2020, 10, 16728.	3.3	3
205	Proper names from story recall are associated with beta-amyloid in cognitively unimpaired adults at risk for Alzheimer's disease. <i>Cortex</i> , 2020, 131, 137-150.	2.4	17
206	Depression screening in cognitively normal older adults: Measurement bias according to subjective memory decline, brain amyloid burden, cognitive function, and sex. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12107.	2.4	3
207	Composite neurocognitive endpoints in Alzheimer's disease clinical trials: A commentary. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12010.	2.4	1
208	Commentary on Composite cognitive and functional measures for early stage Alzheimer's disease trials. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12012.	2.4	2
209	Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 Study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12118.	2.4	12
210	Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals. <i>Nature Communications</i> , 2020, 11, 6024.	12.8	43
211	Association of β^2 -Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals. <i>Neurology</i> , 2021, 96, e662-e670.	1.1	34
212	AD-Related CSF Biomarkers Across Distinct Levels of Cognitive Impairment: Correlations With Global Cognitive State. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2021, 34, 659-667.	2.3	6
213	Association of CSF $A\beta^2$, amyloid PET, and cognition in cognitively unimpaired elderly adults. <i>Neurology</i> , 2020, 95, e2075-e2085.	1.1	31
214	Anti-amyloid- β^2 protein agents for the treatment of Alzheimer's disease: an update on emerging drugs. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 319-335.	2.4	57
215	BHA-CS: A novel cognitive composite for Alzheimer's disease and related disorders. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12042.	2.4	12
216	Sex Mediates Relationships Between Regional Tau Pathology and Cognitive Decline. <i>Annals of Neurology</i> , 2020, 88, 921-932.	5.3	63
217	Quantitative detection and staging of presymptomatic cognitive decline in familial Alzheimer's disease: a retrospective cohort analysis. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 126.	6.2	13

#	ARTICLE	IF	CITATIONS
218	THE TRIAL-READY COHORT FOR PRECLINICAL/PRODROMAL ALZHEIMER'S DISEASE (TRC-PAD) PROJECT: AN OVERVIEW. <i>Journal of prevention of Alzheimer's disease</i> , The, 2020, 7, 1-5.	2.7	17
219	Exploring a Cost-Efficient Model for Predicting Cerebral A β Burden Using MRI and Neuropsychological Markers in the ADNI-2 Cohort. <i>Journal of Personalized Medicine</i> , 2020, 10, 197.	2.5	0
220	Rationale and protocol of the StayFitLonger study: a multicentre trial to measure efficacy and adherence of a home-based computerised multidomain intervention in healthy older adults. <i>BMC Geriatrics</i> , 2020, 20, 315.	2.7	6
221	The preclinical amyloid sensitive composite to determine subtle cognitive differences in preclinical Alzheimer's disease. <i>Scientific Reports</i> , 2020, 10, 13583.	3.3	7
222	Normalization of CSF pTau measurement by A β 40 improves its performance as a biomarker of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 97.	6.2	31
223	Quantitative informant- and self-reports of subjective cognitive decline predict amyloid beta PET outcomes in cognitively unimpaired individuals independently of age and APOE ϵ 4. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12127.	2.4	6
224	Analyzing large Alzheimer's disease cognitive datasets: Considerations and challenges. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12135.	2.4	5
225	Development of a novel cognitive composite outcome to assess therapeutic effects of exercise in the EXERT trial for adults with MCI: The ADAS-Cog-Exec. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12059.	3.7	5
226	Extensive memory testing improves prediction of progression to MCI in late middle age. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12004.	2.4	13
227	Composite cognitive and functional measures for early stage Alzheimer's disease trials. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12017.	2.4	36
228	The Alzheimer's Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 66.	6.2	19
229	The dynamics of biomarkers across the clinical spectrum of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 74.	6.2	53
230	Translational Scoring of Candidate Treatments for Alzheimer's Disease: A Systematic Approach. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 22-37.	1.5	5
231	Counterpoint to Jin et al, On weighted composite scores for early Alzheimer's trials. <i>Pharm Stat.</i> 18 (2):239-47, 2019, DOI: 10.1002/pst.1920. <i>Pharmaceutical Statistics</i> , 2020, 19, 492-493.	1.3	0
232	APOE- ϵ 4 Shapes the Cerebral Organization in Cognitively Intact Individuals as Reflected by Structural Gray Matter Networks. <i>Cerebral Cortex</i> , 2020, 30, 4110-4120.	2.9	7
233	Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults. <i>Neurology</i> , 2020, 94, e1512-e1524.	1.1	53
234	Neurofilament Light Predicts Decline in Attention but Not Episodic Memory in Preclinical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1119-1129.	2.6	14
235	Impact of urban environmental exposures on cognitive performance and brain structure of healthy individuals at risk for Alzheimer's dementia. <i>Environment International</i> , 2020, 138, 105546.	10.0	69

#	ARTICLE	IF	CITATIONS
236	Blood biomarkers of traumatic brain injury and cognitive impairment in older veterans. <i>Neurology</i> , 2020, 95, e1126-e1133.	1.1	55
237	Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers. <i>Neurology</i> , 2020, 95, e1312-e1321.	1.1	7
238	Minor neuropsychological deficits in patients with subjective cognitive decline. <i>Neurology</i> , 2020, 95, e1134-e1143.	1.1	58
239	Modelling prognostic trajectories of cognitive decline due to Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2020, 26, 102199.	2.7	48
240	Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCE project. <i>Neurobiology of Aging</i> , 2020, 89, 99-107.	3.1	34
241	Augmenting Computerized Cognitive Training With Vortioxetine for Age-Related Cognitive Decline: A Randomized Controlled Trial. <i>American Journal of Psychiatry</i> , 2020, 177, 548-555.	7.2	31
242	Amyloid-beta burden predicts prospective decline in body mass index in clinically normal adults. <i>Neurobiology of Aging</i> , 2020, 93, 124-130.	3.1	27
243	Self-reported health behaviors and longitudinal cognitive performance in late middle age: Results from the Wisconsin Registry for Alzheimer's Prevention. <i>PLoS ONE</i> , 2020, 15, e0221985.	2.5	13
244	The A4 study: β -amyloid and cognition in 4432 cognitively unimpaired adults. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 776-785.	3.7	43
245	The Cognitive Functional Composite is sensitive to clinical progression in early dementia: Longitudinal findings from the Catch-Cog study cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12020.	3.7	18
246	Concussion and long-term cognitive impairment among professional or elite sport-persons: a systematic review. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 455-468.	1.9	39
247	Longitudinal Cognitive and Biomarker Measurements Support a Unidirectional Pathway in Alzheimer's Disease Pathophysiology. <i>Biological Psychiatry</i> , 2021, 89, 786-794.	1.3	48
248	Association Between Apolipoprotein E ϵ 2 vs ϵ 4, Age, and β -Amyloid in Adults Without Cognitive Impairment. <i>JAMA Neurology</i> , 2021, 78, 229.	9.0	28
249	Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 426-438.	1.8	30
250	Mesial temporal tau is related to worse cognitive performance and greater neocortical tau load in amyloid- β -negative cognitively normal individuals. <i>Neurobiology of Aging</i> , 2021, 97, 41-48.	3.1	23
251	Kidney Function and Cognitive Decline in Older Adults: Examining the Role of Neurodegeneration. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 651-659.	2.6	12
252	Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation. <i>Neurology</i> , 2021, 96, e619-e631.	1.1	45
253	Functional Ensemble Survival Tree: Dynamic Prediction of Alzheimer's Disease Progression Accommodating Multiple Time-Varying Covariates. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2021, 70, 66-79.	1.0	9

#	ARTICLE	IF	CITATIONS
254	An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum. <i>Alzheimer's and Dementia</i> , 2021, 17, 431-445.	0.8	80
255	An examination of reliable change methods for measuring cognitive change with the Cogstate Computerized Battery: Research and clinical implications. <i>Archives of Clinical Neuropsychology</i> , 2021, 36, 597-612.	0.5	8
256	A short digital eye-tracking assessment predicts cognitive status among adults. <i>GeroScience</i> , 2021, 43, 297-308.	4.6	17
257	Association between composite scores of domain-specific cognitive functions and regional patterns of atrophy and functional connectivity in the Alzheimer's disease spectrum. <i>NeuroImage: Clinical</i> , 2021, 29, 102533.	2.7	15
258	Sleep and longitudinal cognitive performance in preclinical and early symptomatic Alzheimer's disease. <i>Brain</i> , 2021, 144, 2852-2862.	7.6	62
259	Cardiorespiratory fitness mitigates brain atrophy and cognitive decline in adults at risk for Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12212.	2.4	16
260	Cohort-Specific Optimization of Models Predicting Preclinical Alzheimer's Disease, to Enhance Screening Performance in the Middle of Preclinical Alzheimer's Disease Clinical Studies. <i>Journal of Prevention of Alzheimer's Disease</i> , 2021, 8, 1-10.	2.7	0
261	Feasibility and validation of a web-based platform for the self-administered patient collection of demographics, health status, anxiety, depression, and cognition in community dwelling elderly. <i>PLoS ONE</i> , 2021, 16, e0244962.	2.5	7
263	Prevention of cognitive decline in subjective cognitive decline APOE ϵ 4 carriers after EGCG and a multimodal intervention (PENSA): Study design. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12155.	3.7	13
264	Feasibility study of assessing the Preclinical Alzheimer Cognitive Composite (PACC) score via videoconferencing. <i>Journal of Neurology</i> , 2021, 268, 2228-2237.	3.6	7
265	Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer's disease: findings from the Colombia-Boston (COLBOS) biomarker study. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 27.	6.2	34
267	Association of Digital Clock Drawing With PET Amyloid and Tau Pathology in Normal Older Adults. <i>Neurology</i> , 2021, 96, e1844-e1854.	1.1	38
268	Time between milestone events in the Alzheimer's disease amyloid cascade. <i>NeuroImage</i> , 2021, 227, 117676.	4.2	20
269	A novel estimand to adjust for rescue treatment in randomized clinical trials. <i>Statistics in Medicine</i> , 2021, 40, 2257-2271.	1.6	7
270	SPON1 Is Associated with Amyloid- β and APOE ϵ 4-Related Cognitive Decline in Cognitively Normal Adults. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 111-120.	2.2	5
271	Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 46.	6.2	9
272	Prognostic Value of Learning and Retention Measures from the Free and Cued Selective Reminding Test to Identify Incident Mild Cognitive Impairment. <i>Journal of the International Neuropsychological Society</i> , 2022, 28, 292-299.	1.8	5
273	The Free and Cued Selective Reminding Test Predicts Braak Stage. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 175-183.	2.6	6

#	ARTICLE	IF	CITATIONS
274	Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease. JAMA Neurology, 2021, 78, 293.	9.0	57
275	Early identification of Alzheimer's disease in mouse models: Application of deep neural network algorithm to cognitive behavioral parameters. IScience, 2021, 24, 102198.	4.1	14
276	Using Speech Data From Interactions With a Voice Assistant to Predict the Risk of Future Accidents for Older Drivers: Prospective Cohort Study. Journal of Medical Internet Research, 2021, 23, e27667.	4.3	5
277	Optimizing Subjective Cognitive Decline to Detect Early Cognitive Dysfunction. Journal of Alzheimer's Disease, 2021, 80, 1185-1196.	2.6	10
278	Association of Neighborhood Context, Cognitive Decline, and Cortical Change in an Unimpaired Cohort. Neurology, 2021, 96, e2500-e2512.	1.1	32
279	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. JAMA Neurology, 2021, 78, 396.	9.0	146
280	Elevated plasma neurofilament light predicts a faster rate of cognitive decline over 5 years in participants with objectivelyâ€defined subtle cognitive decline and MCI. Alzheimer's and Dementia, 2021, 17, 1756-1762.	0.8	22
281	Testing Mediation Effects Using Logic of Boolean Matrices. Journal of the American Statistical Association, 2022, 117, 2014-2027.	3.1	8
282	Subjective cognitive complaints at age 70: associations with amyloid and mental health. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1215-1221.	1.9	16
284	Functional Connectivity Between the Posterior Default Mode Network and Parahippocampal Gyrus Is Disrupted in Older Adults with Subjective Cognitive Decline and Correlates with Subjective Memory Ability. Journal of Alzheimer's Disease, 2021, 82, 435-445.	2.6	9
285	Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe. Alzheimer's and Dementia, 2022, 18, 29-42.	0.8	24
286	The <i>BIN1</i> rs744373 Alzheimer's disease risk SNP is associated with faster AÎ²â€associated tau accumulation and cognitive decline. Alzheimer's and Dementia, 2022, 18, 103-115.	0.8	24
287	Plasma biomarkers of Alzheimerâ€™s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nature Communications, 2021, 12, 3555.	12.8	115
288	Protocol of the Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research (CHARIOT): Prospective Readiness cOHort (PRO) SubStudy. BMJ Open, 2021, 11, e043114.	1.9	4
289	Machine Learning Detects Distinct Subtypes of Minimal Cognitive Impairment. Journal of Signal Processing Systems, 2022, 94, 437-443.	2.1	2
290	Validity Evidence for the Research Category, â€œCognitively Unimpaired â€ Declining,â€ as a Risk Marker for Mild Cognitive Impairment and Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2021, 13, 688478.	3.4	21
291	Topographical patterns of whole-brain structural alterations in association with genetic risk, cerebrospinal fluid, positron emission tomography biomarkers of Alzheimerâ€™s disease, and neuropsychological measures. Clinical and Translational Imaging, 2021, 9, 439-497.	2.1	0
292	Development of novel measures for Alzheimer's disease prevention trials (NoMAD). Contemporary Clinical Trials, 2021, 106, 106425.	1.8	4

#	ARTICLE	IF	CITATIONS
293	Developing the ATX(N) classification for use across the Alzheimer disease continuum. <i>Nature Reviews Neurology</i> , 2021, 17, 580-589.	10.1	144
294	Topographical Overlapping of the Amyloid- β^2 and Tau Pathologies in the Default Mode Network Predicts Alzheimer's Disease with Higher Specificity. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 407-421.	2.6	10
295	Association of Short and Long Sleep Duration With Amyloid- β^2 Burden and Cognition in Aging. <i>JAMA Neurology</i> , 2021, 78, 1187.	9.0	103
296	Longitudinal analysis of APOE- ϵ^4 genotype with the logical memory delayed recall score in Alzheimer's disease. <i>Journal of Genetics</i> , 2021, 100, 1.	0.7	5
297	Targeting Default Mode Network Dysfunction in Persons at Risk of Alzheimer's Disease with Transcranial Magnetic Stimulation (NEST4AD): Rationale and Study Design. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1-13.	2.6	4
298	Mindfulness Training Improves Cognition and Strengthens Intrinsic Connectivity Between the Hippocampus and Posteromedial Cortex in Healthy Older Adults. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 702796.	3.4	13
299	Associations Between Cognitive Complaints, Memory Performance, Mood, and Amyloid- β^2 Accumulation in Healthy Amyloid Negative Late-Midlife Individuals. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 127-141.	2.6	4
300	Grip strength from midlife as an indicator of later-life brain health and cognition: evidence from a British birth cohort. <i>BMC Geriatrics</i> , 2021, 21, 475.	2.7	18
301	Social Cognition in Patients with Amnesic Mild Cognitive Impairment and Mild Dementia of the Alzheimer Type. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1173-1186.	2.6	1
302	Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 824-857.	0.8	56
303	The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. <i>Nature Reviews Neurology</i> , 2021, 17, 703-714.	10.1	65
304	Abnormal tau in amyloid PET negative individuals. <i>Neurobiology of Aging</i> , 2022, 109, 125-134.	3.1	22
305	DeepAtrophy: Teaching a neural network to detect progressive changes in longitudinal MRI of the hippocampal region in Alzheimer's disease. <i>NeuroImage</i> , 2021, 243, 118514.	4.2	6
306	Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial-Ready Cohort study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12135.	3.7	11
309	Building clinically relevant outcomes across the Alzheimer's disease spectrum. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12181.	3.7	16
310	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. <i>Neurology</i> , 2021, 96, e1632-e1645.	1.1	16
311	Current advances in digital cognitive assessment for preclinical Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12217.	2.4	63
312	Sex-related Differences in Tau Positron Emission Tomography (PET) and the Effects of Hormone Therapy (HT). <i>Alzheimer Disease and Associated Disorders</i> , 2021, 35, 164-168.	1.3	30

#	ARTICLE	IF	CITATIONS
315	Amyloid precursor proteinâ€‘mediated endocytic pathway disruption induces axonal dysfunction and neurodegeneration. Journal of Clinical Investigation, 2016, 126, 1815-1833.	8.2	149
316	Use of High-Frequency In-Home Monitoring Data May Reduce Sample Sizes Needed in Clinical Trials. PLoS ONE, 2015, 10, e0138095.	2.5	80
317	ENDPOINTS FOR PRE-DEMENTIA AD TRIALS: A REPORT FROM THE EU/US/CTAD TASK FORCE. journal of prevention of Alzheimer's disease, The, 2015, 2, 1-8.	2.7	35
318	COGNITIVE/CLINICAL ENDPOINTS FOR PRE-DEMENTIA AD TRIALS. journal of prevention of Alzheimer's disease, The, 2015, 2, 1-3.	2.7	9
319	THE FEASIBILITY OF AT-HOME IPAD COGNITIVE TESTING FOR USE IN CLINICAL TRIALS. journal of prevention of Alzheimer's disease, The, 2016, 3, 1-5.	2.7	39
320	EU/US/CTAD TASK FORCE: LESSONS LEARNED FROM RECENT AND CURRENT ALZHEIMERâ€™S PREVENTION TRIALS. journal of prevention of Alzheimer's disease, The, 2017, 4, 1-9.	2.7	18
321	A Web-Based Multidomain Lifestyle Intervention for Older Adults: The eMIND Randomized Controlled Trial. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-9.	2.7	17
322	Cognitive efficiency in late midlife is linked to lifestyle characteristics and allostatic load. Aging, 2019, 11, 7169-7186.	3.1	14
323	Preclinical progression of neurodegenerative diseases. Nagoya Journal of Medical Science, 2018, 80, 289-298.	0.3	32
324	One-year Outcome of Shanghai Mild Cognitive Impairment Cohort Study. Current Alzheimer Research, 2019, 16, 156-165.	1.4	13
325	Device-Embedded Cameras for Eye Trackingâ€‘Based Cognitive Assessment: Validation With Paper-Pencil and Computerized Cognitive Composites. Journal of Medical Internet Research, 2018, 20, e11143.	4.3	31
326	Objective subtle cognitive decline and plasma phosphorylated tau181: Early markers of Alzheimer's diseaseâ€‘related declines. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12238.	2.4	11
327	Alzheimer Identification through DNA Methylation and Artificial Intelligence Techniques. Mathematics, 2021, 9, 2482.	2.2	4
328	Age, vascular disease, and Alzheimerâ€™s disease pathologies in amyloid negative elderly adults. Alzheimer's Research and Therapy, 2021, 13, 174.	6.2	15
329	Sequential pathway inference for multimodal neuroimaging analysis. Stat, 2022, 11, e433.	0.4	1
330	Concussion and longâ€‘term cognitive function among rugby playersâ€‘The BRAIN Study. Alzheimer's and Dementia, 2022, 18, 1164-1176.	0.8	11
331	Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum. Alzheimer's and Dementia, 2022, 18, 1370-1382.	0.8	17
333	Association of peripheral blood DNA methylation level with Alzheimerâ€™s disease progression. Clinical Epigenetics, 2021, 13, 191.	4.1	29

#	ARTICLE	IF	CITATIONS
334	A cross-sectional study of memory and executive functions in patients with sporadic inclusion body myositis. Muscle and Nerve, 2021, 65, 105.	2.2	0
335	Cognitive Assessment in Alzheimer's Disease Clinical Trials. Methods in Molecular Biology, 2018, 1750, 355-362.	0.9	0
343	Limitations of clinical trial sample size estimate by subtraction of two measurements. Statistics in Medicine, 2022, 41, 1137-1147.	1.6	2
344	Efficacy and Cost-effectiveness of Promotion Methods to Recruit Participants to an Online Screening Registry for Alzheimer Disease Prevention Trials: Observational Study. Journal of Medical Internet Research, 2021, 23, e26284.	4.3	4
346	PREDICTING AMYLOID BURDEN TO ACCELERATE RECRUITMENT OF SECONDARY PREVENTION CLINICAL TRIALS. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-6.	2.7	23
347	The Computerized Cognitive Composite (C3) in A4, an Alzheimer's Disease Secondary Prevention Trial. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-9.	2.7	25
348	Application of Digital Cognitive Biomarkers for Alzheimer's Disease: Identifying Cognitive Process Changes and Impending Cognitive Decline. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-4.	2.7	3
350	Cognitive dispersion and ApoEε4 genotype predict dementia diagnosis in 8-year follow-up of the oldest-old. Age and Ageing, 2021, 50, 868-874.	1.6	5
351	COMPUTERIZED COGNITIVE TESTING FOR USE IN CLINICAL TRIALS: A COMPARISON OF THE NIH TOOLBOX AND COGSTATE C3 BATTERIES. journal of prevention of Alzheimer's disease, The, 2017, 4, 1-9.	2.7	46
352	Establishing Composite Cognitive Endpoints for Use in Preclinical Alzheimer's Disease Trials. journal of prevention of Alzheimer's disease, The, 2015, 2, 2-3.	2.7	23
353	A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS). journal of prevention of Alzheimer's disease, The, 2015, 2, 227-241.	2.7	18
354	ARMADA: Assessing reliable measurement in Alzheimer's disease and cognitive aging project methods. Alzheimer's and Dementia, 2022, 18, 1449-1460.	0.8	9
355	Decreased Resting-State Functional Complexity in Elderly with Subjective Cognitive Decline. Entropy, 2021, 23, 1591.	2.2	4
357	Higher Coffee Consumption Is Associated With Slower Cognitive Decline and Less Cerebral Aβ ² -Amyloid Accumulation Over 126 Months: Data From the Australian Imaging, Biomarkers, and Lifestyle Study. Frontiers in Aging Neuroscience, 2021, 13, 744872.	3.4	17
358	Different rates of cognitive decline in autosomal dominant and late-onset Alzheimer disease. Alzheimer's and Dementia, 2022, 18, 1754-1764.	0.8	4
359	A COMBINED MEASURE OF COGNITION AND FUNCTION FOR CLINICAL TRIALS: THE INTEGRATED ALZHEIMER'S DISEASE RATING SCALE (IADRS). journal of prevention of Alzheimer's disease, The, 2015, 2, 1-15.	2.7	33
360	ESTABLISHING COMPOSITE COGNITIVE ENDPOINTS FOR USE IN PRECLINICAL ALZHEIMER'S DISEASE TRIALS. journal of prevention of Alzheimer's disease, The, 2015, 2, 1-2.	2.7	10
361	Reproducibility and replicability of high-frequency, in-home digital biomarkers in reducing sample sizes for clinical trials. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12220.	3.7	8

#	ARTICLE	IF	CITATIONS
362	Electrophysiological resting state brain network and episodic memory in healthy aging adults. <i>NeuroImage</i> , 2022, 253, 118926.	4.2	4
363	Experiences of Participation in a Multimodal Preventive Trial MIND-ADMINI Among Persons with Prodromal Alzheimer's Disease: A Qualitative Study. <i>Journal of Multidisciplinary Healthcare</i> , 2022, Volume 15, 219-234.	2.7	3
364	Dual Task Performance Is Associated with Amyloidosis in Cognitively Healthy Adults. <i>Journal of prevention of Alzheimer's disease, The</i> , 2022, 9, 297-305.	2.7	2
366	Ketone Ester Effects on Biomarkers of Brain Metabolism and Cognitive Performance in Cognitively Intact Adults \geq 55 Years Old. A Study Protocol for a Double-Blinded Randomized Controlled Clinical Trial. <i>Journal of prevention of Alzheimer's disease, The</i> , 2022, 9, 1-12.	2.7	1
367	Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial. <i>Journal of prevention of Alzheimer's disease, The</i> , 2022, 9, 255-261.	2.7	4
368	Monthly At-Home Computerized Cognitive Testing to Detect Diminished Practice Effects in Preclinical Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 800126.	3.4	19
369	Prescription Medications and Co-Morbidities in Late Middle-Age are Associated with Greater Cognitive Declines: Results from WRAP. <i>Frontiers in Aging</i> , 2022, 2, .	2.6	4
370	Longitudinal amyloid cognitive composite in preclinical Alzheimer's disease. <i>European Journal of Neurology</i> , 2022, 29, 980-989.	3.3	2
371	Development of Apathy, Anxiety, and Depression in Cognitively Unimpaired Older Adults: Effects of Alzheimer's Disease Pathology and Cognitive Decline. <i>Biological Psychiatry</i> , 2022, 92, 34-43.	1.3	21
372	Neuroprotective Effect of HIIT against GFAP Hypertrophy through Mitochondrial Dynamics in APP/PS1 Mice. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-14.	4.0	3
373	Impact of sex and ϵ APOE ϵ 4 on the association of cognition and hippocampal volume in clinically normal, amyloid positive adults. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12271.	2.4	4
374	Sulcal morphology as cognitive decline predictor in older adults with memory complaints. <i>Neurobiology of Aging</i> , 2022, 113, 84-94.	3.1	1
375	Intracranial internal carotid artery calcification is not predictive of future cognitive decline. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 32.	6.2	6
376	A three-range approach enhances the prognostic utility of CSF biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, e12270.	3.7	3
378	Differential associations of visual memory with hippocampal subfields in subjective cognitive decline and amnesic mild cognitive impairment. <i>BMC Geriatrics</i> , 2022, 22, 153.	2.7	16
379	Progression from Subjective Cognitive Decline to Mild Cognitive Impairment or Dementia: The Role of Baseline Cognitive Performance. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 1763-1774.	2.6	2
380	The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 306-318.	46.4	273
381	Cognitive differences across ethnoracial category, socioeconomic status across the Alzheimer's disease spectrum: Can an ability discrepancy score level the playing field?. <i>Memory and Cognition</i> , 2023, 51, 543-560.	1.6	5

#	ARTICLE	IF	CITATIONS
382	ATRI and ACTC: Academic Programs to Accelerate Alzheimer's Disease Drug Development. , 2022, , 177-189.		0
383	APOE- ϵ 4 modulates the association among plasma A β 242/A β 240, vascular diseases, neurodegeneration and cognitive decline in non-demented elderly adults. Translational Psychiatry, 2022, 12, 128.	4.8	11
384	Alzheimer's Disease Drug Development: A Research and Development Ecosystem. , 2022, , 1-24.		2
385	The Importance of Phase 2 in Drug Development for Alzheimer's Disease. , 2022, , 150-161.		0
386	Baseline Microglial Activation Correlates With Brain Amyloidosis and Longitudinal Cognitive Decline in Alzheimer Disease. Neurology: Neuroimmunology and Neuroinflammation, 2022, 9, .	6.0	16
387	Detecting Alzheimer Disease Clinically. Neurology, 2022, 98, 607-608.	1.1	1
389	Association of Emerging β -Amyloid and Tau Pathology With Early Cognitive Changes in Clinically Normal Older Adults. Neurology, 2022, 98, .	1.1	20
390	Statistical Considerations in the Design and Analysis of Alzheimer's Disease Clinical Trials. , 2022, , 232-248.		0
391	Mesial temporal tau in amyloid- β -negative cognitively normal older persons. Alzheimer's Research and Therapy, 2022, 14, 51.	6.2	12
392	A robust and interpretable machine learning approach using multimodal biological data to predict future pathological tau accumulation. Nature Communications, 2022, 13, 1887.	12.8	16
394	Categorical predictive and disease progression modeling in the early stage of Alzheimer's disease. Journal of Neuroscience Methods, 2022, 374, 109581.	2.5	2
395	Ethnic differences in the frequency of β -amyloid deposition in cognitively normal individuals. Neurobiology of Aging, 2022, 114, 27-37.	3.1	3
396	CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease. Neurobiology of Disease, 2022, 168, 105714.	4.4	7
397	Insulin resistance, cognition and Alzheimer's disease biomarkers: Evidence that CSF A β 242 moderates the association between insulin resistance and increased CSF tau levels. Neurobiology of Aging, 2022, 114, 38-48.	3.1	5
399	Association of CSF A β 2 ₃₈ Levels With Risk of Alzheimer Disease-Related Decline. Neurology, 2022, 98, .	1.1	16
400	Negative affective burden is associated with higher resting-state functional connectivity in subjective cognitive decline. Scientific Reports, 2022, 12, 6212.	3.3	4
401	Decision-Making Profiles and Their Associations with Cognitive Performance in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2022, 87, 1215-1227.	2.6	1
402	Diabetic patients treated with metformin during early stages of Alzheimer's disease show a better integral performance: data from ADNI study. GeroScience, 2022, 44, 1791-1805.	4.6	7

#	ARTICLE	IF	CITATIONS
403	Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume. <i>GeroScience</i> , 2022, 44, 1807-1823.	4.6	19
404	Investigating the combination of plasma amyloid-beta and geroscience biomarkers on the incidence of clinically meaningful cognitive decline in older adults. <i>GeroScience</i> , 2022, 44, 1489-1503.	4.6	3
407	Impaired Affordance Perception as the Basis of Tool Use Deficiency in Alzheimer's Disease. <i>Healthcare (Switzerland)</i> , 2022, 10, 839.	2.0	2
408	Association of β^2 -Amyloid and Vascular Risk on Longitudinal Patterns of Brain Atrophy. <i>Neurology</i> , 2022, 99, .	1.1	8
411	Anti-Amyloid- β^2 Immunotherapy: A Leading Novel Avenue for Alzheimer's Disease. <i>Mini-Reviews in Medicinal Chemistry</i> , 2022, 22, .	2.4	0
412	Systemic perturbations of the kynurenine pathway precede progression to dementia independently of amyloid- β^2 . <i>Neurobiology of Disease</i> , 2022, 171, 105783.	4.4	5
413	Differential Patterns of Domain-Specific Cognitive Complaints and Awareness Across the Alzheimer's Disease Spectrum. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	3.4	4
414	Physical activity is associated with increased resting-state functional connectivity in networks predictive of cognitive decline in clinically unimpaired older adults. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	2.4	0
415	Item-Level Story Recall Predictors of Amyloid-Beta in Late Middle-Aged Adults at Increased Risk for Alzheimer's Disease. <i>Frontiers in Psychology</i> , 0, 13, .	2.1	4
416	Contribution of Memory Tests to Early Identification of Conversion from Amnesic Mild Cognitive Impairment to Dementia. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1397-1409.	2.6	5
417	Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages. <i>Neurology</i> , 2022, 99, .	1.1	20
418	Neuropsychological Decline Stratifies Dementia Risk in Cognitively Unimpaired and Impaired Older Adults. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	3.4	0
419	Self- and Partner-Reported Subjective Memory Complaints: Association with Objective Cognitive Impairment and Risk of Decline. <i>Journal of Alzheimer's Disease Reports</i> , 2022, 6, 411-430.	2.2	4
420	Identification of Leukocyte Surface P2X7 as a Biomarker Associated with Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7867.	4.1	5
421	Temporal Cortex Microarray Analysis Revealed Impaired Ribosomal Biogenesis and Hyperactivity of the Glutamatergic System: An Early Signature of Asymptomatic Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 0, 16, .	2.8	3
422	Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment. <i>JAMA Neurology</i> , 2022, 79, 975.	9.0	36
423	Plasma $A\beta^{42/40}$ ratio, $p\tau^{181}$, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort. <i>Alzheimer's and Dementia</i> , 2023, 19, 1117-1134.	0.8	44
424	Harmonizing the preclinical Alzheimer cognitive composite for multicohort studies.. <i>Neuropsychology</i> , 2023, 37, 436-449.	1.3	3

#	ARTICLE	IF	CITATIONS
425	The Link between Obstructive Sleep Apnea and Neurocognitive Impairment: An Official American Thoracic Society Workshop Report. <i>Annals of the American Thoracic Society</i> , 2022, 19, 1245-1256.	3.2	33
426	The relationship between cognitive reserve and cognition in healthy adults: a systematic review. <i>Current Psychology</i> , 2023, 42, 24751-24763.	2.8	5
427	Straight and Divergent Pathways to Cognitive State: Seven Decades of Follow-Up in the British 1946 Birth Cohort. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-9.	2.6	1
428	The AHEAD 3â€45 Study: Design of a prevention trial for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 1227-1233.	0.8	34
429	Plasma p-tau231 and p-tau217 as state markers of amyloid-Î² pathology in preclinical Alzheimerâ€™s disease. <i>Nature Medicine</i> , 0, , .	30.7	58
430	Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	6.2	3
431	Association between urate-lowering therapies and cognitive decline in community-dwelling older adults. <i>Scientific Reports</i> , 2022, 12, .	3.3	0
432	Associations of the Lifestyle for Brain Health index with longitudinal cognition and brain amyloid beta in clinically unimpaired older adults: Findings from the Wisconsin Registry for Alzheimer's Prevention. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	2.4	0
433	Experiences of Active Everyday Life Among Persons with Prodromal Alzheimerâ€™s Disease: A Qualitative Study. <i>Journal of Multidisciplinary Healthcare</i> , 0, Volume 15, 1921-1932.	2.7	1
434	Unsupervised high-frequency smartphone-based cognitive assessments are reliable, valid, and feasible in older adults at risk for Alzheimerâ€™s disease. <i>Journal of the International Neuropsychological Society</i> , 2023, 29, 459-471.	1.8	16
435	Association of Presynaptic Loss with Alzheimer's Disease and Cognitive Decline. <i>Annals of Neurology</i> , 2022, 92, 1001-1015.	5.3	16
436	Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 708-720.	0.8	16
437	Validation of a Remote and Fully Automated Story Recall Task to Assess for Early Cognitive Impairment in Older Adults: Longitudinal Case-Control Observational Study. <i>JMIR Aging</i> , 2022, 5, e37090.	3.0	5
439	Effects of a mindfulness-based versus a health self-management intervention on objective cognitive performance in older adults with subjective cognitive decline (SCD): a secondary analysis of the SCD-Well randomized controlled trial. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	6.2	4
440	Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals. <i>Brain</i> , 2023, 146, 1580-1591.	7.6	15
441	Neuroimaging and clinical characteristics of cognitive migration in community-dwelling older adults. <i>NeuroImage: Clinical</i> , 2022, 36, 103232.	2.7	1
442	Associations of erythrocyte omega-3 fatty acids with cognition, brain imaging and biomarkers in the Alzheimerâ€™s disease neuroimaging initiative: cross-sectional and longitudinal retrospective analyses. <i>American Journal of Clinical Nutrition</i> , 2022, 116, 1492-1506.	4.7	7
444	Preclinical Alzheimerâ€™s dementia: a useful concept or another dead end?. <i>European Journal of Ageing</i> , 2022, 19, 997-1004.	2.8	5

#	ARTICLE	IF	CITATIONS
445	Sleep disturbance is associated with mild cognitive impairment: a community population-based cross-sectional study. BMC Public Health, 2022, 22, .	2.9	4
446	Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nature Medicine, 2022, 28, 2381-2387.	30.7	99
447	Genetically predicted telomere length and Alzheimer's disease endophenotypes: a Mendelian randomization study. Alzheimer's Research and Therapy, 2022, 14, .	6.2	11
448	Unsupervised mobile app-based cognitive testing in a population-based study of older adults born 1944. Frontiers in Digital Health, 0, 4, .	2.8	6
450	Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer's disease. Nature Communications, 2022, 13, .	12.8	40
451	Machine learning based multi-modal prediction of future decline toward Alzheimer's disease: An empirical study. PLoS ONE, 2022, 17, e0277322.	2.5	6
452	Vascular endothelial cadherin as a marker of endothelial injury in preclinical Alzheimer disease. Annals of Clinical and Translational Neurology, 2022, 9, 1926-1940.	3.7	9
454	Connectivity between default mode and frontoparietal networks mediates the association between global amyloid β and episodic memory. Human Brain Mapping, 2023, 44, 1147-1157.	3.6	4
455	Differential roles of A β 42/40, p-tau231 and p-tau217 for Alzheimer's disease trial selection and disease monitoring. Nature Medicine, 2022, 28, 2555-2562.	30.7	101
456	Presynaptic membrane protein dysfunction occurs prior to neurodegeneration and predicts faster cognitive decline. Alzheimer's and Dementia, 2023, 19, 2408-2419.	0.8	7
457	Effects of Mindfulness Training and Exercise on Cognitive Function in Older Adults. JAMA - Journal of the American Medical Association, 2022, 328, 2218.	7.4	32
458	Genetic risk for attention-deficit/hyperactivity disorder predicts cognitive decline and development of Alzheimer's disease pathophysiology in cognitively unimpaired older adults. Molecular Psychiatry, 2023, 28, 1248-1255.	7.9	10
459	Mayo-PACC: A parsimonious preclinical Alzheimer's disease cognitive composite comprised of public-domain measures to facilitate clinical translation. Alzheimer's and Dementia, 2023, 19, 2575-2584.	0.8	6
460	New Therapeutics in Alzheimer's Disease Longitudinal Cohort study (NTAD): study protocol. BMJ Open, 2022, 12, e055135.	1.9	2
461	Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: A multi-cohort study. Alzheimer's and Dementia, 2023, 19, 2943-2955.	0.8	12
462	Natural cubic splines for the analysis of Alzheimer's clinical trials. Pharmaceutical Statistics, 0, , .	1.3	2
463	The relationship between objective physical activity and change in cognitive function. Alzheimer's and Dementia, 2023, 19, 2984-2993.	0.8	3
464	Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit. Alzheimer's Research and Therapy, 2023, 15, .	6.2	4

#	ARTICLE	IF	CITATIONS
466	Genetically identical twin-pair difference models support the amyloid cascade hypothesis. <i>Brain</i> , 0, , .	7.6	1
467	A comprehensive assessment of age at menopause with well-characterized cognition at 70Âyears: A population-based British birth cohort. <i>Maturitas</i> , 2023, 170, 31-38.	2.4	2
468	Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers. <i>JAMA Neurology</i> , 2023, 80, 360.	9.0	58
469	Modern Methods of Diagnostics and Treatment of Neurodegenerative Diseases and Depression. <i>Diagnostics</i> , 2023, 13, 573.	2.6	9
471	Validation of a digit symbol substitution test for use in supervised and unsupervised assessment in mild Alzheimerâ€™s disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2022, 44, 768-779.	1.3	0
472	Associations between self-reported sleep patterns and health, cognition and amyloid measures: results from the Wisconsin Registry for Alzheimerâ€™s Prevention. <i>Brain Communications</i> , 2023, 5, .	3.3	2
473	Contribution of Alzheimer's disease pathology to biological and clinical progression: A longitudinal study across two cohorts. <i>Alzheimer's and Dementia</i> , 0, , .	0.8	0
474	Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimerâ€™s disease. <i>Alzheimer's Research and Therapy</i> , 2023, 15, .	6.2	1
476	Classification and prediction of cognitive trajectories of cognitively unimpaired individuals. <i>Frontiers in Aging Neuroscience</i> , 0, 15, .	3.4	1
477	Ginkgo biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review. <i>Neuropsychiatric Disease and Treatment</i> , 0, Volume 19, 647-660.	2.2	4
478	Identification of plasma metabolites associated with modifiable risk factors and endophenotypes reflecting Alzheimerâ€™s disease pathology. <i>European Journal of Epidemiology</i> , 2023, 38, 559-571.	5.7	2
479	Directed Functional Brain Connectivity is Altered in Sub-threshold Amyloid-Î² Accumulation in Cognitively Normal Individuals. <i>Neuroscience Insights</i> , 2023, 18, 263310552311616.	1.6	0
480	Traceability and comparability through crosswalks with the NeuroMET Memory Metric. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
482	Association of Age at Menopause and Hormone Therapy Use With Tau and Î²-Amyloid Positron Emission Tomography. <i>JAMA Neurology</i> , 2023, 80, 462.	9.0	21
483	Validation study of â€œSantÃ©-Cerveauâ€, a digital tool for early cognitive changes identification. <i>Alzheimer's Research and Therapy</i> , 2023, 15, .	6.2	1
484	Association of Stages of Objective Memory Impairment With Incident Symptomatic Cognitive Impairment in Cognitively Normal Individuals. <i>Neurology</i> , 2023, 100, .	1.1	2
485	Genetic Moderation of the Association of Î²-Amyloid With Cognition and MRI Brain Structure in Alzheimer Disease. <i>Neurology</i> , 2023, 101, .	1.1	0
486	Association Between Meditative Capacities and Cognitive Functions in Healthy Older Adults Naïve to Meditation Practice. <i>Mindfulness</i> , 2023, 14, 695-707.	2.8	0

#	ARTICLE	IF	CITATIONS
487	Intensive assessment of executive functions derived from performance in cognitive training games. IScience, 2023, 26, 106886.	4.1	0
490	Habitual dietary nitrate intake and cognition in the Australian Imaging, Biomarkers and Lifestyle Study of ageing: A prospective cohort study. Clinical Nutrition, 2023, 42, 1251-1259.	5.0	2
491	Impact of asthma on the brain: evidence from diffusion MRI, CSF biomarkers and cognitive decline. Brain Communications, 2023, 5, .	3.3	6
492	Nonlinear changes in delayed functional network topology in Alzheimer's disease: relationship with amyloid and tau pathology. Alzheimer's Research and Therapy, 2023, 15, .	6.2	1
493	A comparison of story-recall metrics to predict hippocampal volume in older adults with and without cognitive impairment. Clinical Neuropsychologist, 2024, 38, 453-470.	2.3	0
494	Protective effects of sleep duration and physical activity on cognitive performance are influenced by β 2-amyloid and brain volume but not tau burden among cognitively unimpaired older adults. NeuroImage: Clinical, 2023, 39, 103460.	2.7	0
495	Associations of healthy lifestyle and socioeconomic status with cognitive function in U.S. older adults. Scientific Reports, 2023, 13, .	3.3	3
496	Detection and treatment of Alzheimer's disease in its preclinical stage. Nature Aging, 2023, 3, 520-531.	11.6	12
497	Clinical utility of an antibody-free LC-MS method to detect brain amyloid deposition in cognitively unimpaired individuals from the screening visit of the A4 Study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2023, 15, .	2.4	2
498	Recommendations on the Selection, Development, and Modification of Performance Outcome Assessments: A Good Practices Report of an ISPOR Task Force. Value in Health, 2023, 26, 959-967.	0.3	1
499	Precipitating Mechanisms of Falls in Preclinical Alzheimer's Disease. Journal of Alzheimer's Disease Reports, 2023, 7, 739-750.	2.2	1
501	Trial of Solanezumab in Preclinical Alzheimer's Disease. New England Journal of Medicine, 2023, 389, 1096-1107.	27.0	31
502	The effect of mindfulness-based intervention on cognitively unimpaired older adults' cognitive function and sleep quality: a systematic review and meta-analysis. Aging and Mental Health, 2024, 28, 23-35.	2.8	0
503	A robust harmonization approach for cognitive data from multiple aging and dementia cohorts. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2023, 15, .	2.4	1
504	Meaningful benefit and minimal clinically important difference (MCID) in Alzheimer's disease: Open peer commentary. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2023, 9, .	3.7	0
505	Prevalence and Clinical Implications of a β 2-Amyloid "Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease. JAMA Neurology, 2023, 80, 969.	9.0	4
506	Prediction of mental effort derived from an automated vocal biomarker using machine learning in a large-scale remote sample. Frontiers in Artificial Intelligence, 0, 6, .	3.4	0
508	Exposure assessment for repeated sub-concussive head impacts in soccer: The Health and Ageing Data IN the Game of football (HEADING) study. International Journal of Hygiene and Environmental Health, 2023, 253, 114235.	4.3	0

#	ARTICLE	IF	CITATIONS
509	Sex Differences in the Associations of Obesity with Tau, Amyloid PET, and Cognitive Outcomes in Preclinical Alzheimer's Disease: Cross-Sectional A4 Study. <i>Journal of Alzheimer's Disease</i> , 2023, , 1-10.	2.6	0
510	Meta-Analysis of Animal Fluency Performance in Amnesic Mild Cognitive Impairment and Cognitively Unimpaired Older Adults. <i>Alzheimer Disease and Associated Disorders</i> , 2023, 37, 259-264.	1.3	0
511	Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid- β Positivity. <i>JAMA Neurology</i> , 2023, 80, 1051.	9.0	7
512	Sex differences in the association between tau PET and cognitive performance in a non-Hispanic White cohort with preclinical AD. <i>Alzheimer's and Dementia</i> , 2024, 20, 25-33.	0.8	0
513	Linguistic, visuospatial, and kinematic writing characteristics in cognitively impaired patients with beta-amyloid deposition. <i>Frontiers in Aging Neuroscience</i> , 0, 15, .	3.4	0
514	Astrocyte biomarkers GFAP and YKL40 mediate early Alzheimer's disease progression. <i>Alzheimer's and Dementia</i> , 2024, 20, 483-493.	0.8	3
515	Recent Advances in Neuropsychological Test Interpretation for Clinical Practice. <i>Neuropsychology Review</i> , 0, , .	4.9	4
516	Association of APOE- ϵ 4 and GAP-43-related presynaptic loss with β -amyloid, tau, neurodegeneration, and cognitive decline. <i>Neurobiology of Aging</i> , 2023, 132, 209-219.	3.1	0
518	Identifying individuals with non-Alzheimer's disease co-pathologies: A precision medicine approach to clinical trials in sporadic Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2024, 20, 421-436.	0.8	0
519	Investigating predictors of progression from mild cognitive impairment to Alzheimer's disease based on different time intervals. <i>Age and Ageing</i> , 2023, 52, .	1.6	0
520	Modifiable in-hospital factors for 12-month global cognition, post-traumatic stress disorder symptoms, and depression symptoms in adults hospitalized with COVID-19. <i>Influenza and Other Respiratory Viruses</i> , 2023, 17, .	3.4	0
521	Medication and Road Test Performance Among Cognitively Healthy Older Adults. <i>JAMA Network Open</i> , 2023, 6, e2335651.	5.9	2
522	Development of a Cognitive Composite for Preclinical Alzheimer's Disease in Korean Older Adults. <i>Journal of Alzheimer's Disease</i> , 2023, , 1-9.	2.6	0
524	Independent effect of A β burden on cognitive impairment in patients with small subcortical infarction. <i>Alzheimer's Research and Therapy</i> , 2023, 15, .	6.2	0
525	Cognitive impact of multidomain intervention and omega 3 according to blood A β 42/40 ratio: a subgroup analysis from the randomized MAPT trial. <i>Alzheimer's Research and Therapy</i> , 2023, 15, .	6.2	0
526	Explainability of random survival forests in predicting conversion risk from mild cognitive impairment to Alzheimer's disease. <i>Brain Informatics</i> , 2023, 10, .	3.0	1
527	Prediction of progression from mild cognitive impairment to Alzheimer's disease with longitudinal and multimodal data. , 0, 2, .		0
528	Cell-type-specific Alzheimer's disease polygenic risk scores are associated with distinct disease processes in Alzheimer's disease. <i>Nature Communications</i> , 2023, 14, .	12.8	1

#	ARTICLE	IF	CITATIONS
529	Assessing depression recurrence, cognitive burden, and neurobiological homeostasis in late life: Design and rationale of the REMBRANDT study. , 2023, , 100038.		0
530	Clinical Features of Subjective Cognitive Decline in The Early Stages of Alzheimerâ€™s Disease. Personalized Psychiatry and Neurology, 2023, 3, 3-14.	0.5	0
531	Assessing the Biological Mechanisms Linking Smoking Behavior and Cognitive Function: A Mediation Analysis of Untargeted Metabolomics. Metabolites, 2023, 13, 1154.	2.9	0
532	Harnessing cognitive trajectory clusterings to examine subclinical decline risk factors. Brain Communications, 0, , .	3.3	0
533	DAT1 and BDNF polymorphisms interact to predict A β and tau pathology. Neurobiology of Aging, 2024, 133, 115-124.	3.1	0
534	Diffusion MRI tracks cortical microstructural changes during the early stages of Alzheimerâ€™s disease. Brain, 2024, 147, 961-969.	7.6	0
535	Vascular risk burden is a key player in the early progression of Alzheimerâ€™s disease. Neurobiology of Aging, 2024, 136, 88-98.	3.1	0
536	Individuals with Alzheimer's disease and low tau burden: Characteristics and implications. Alzheimer's and Dementia, 2024, 20, 2113-2127.	0.8	0
537	Clinical importance in Alzheimerâ€™s disease: effects of anchor agreement and disease severity. Aging Clinical and Experimental Research, 2024, 36, .	2.9	0
538	Multidomain interventions based on a life-course model to prevent dementia in at-risk Chinese older adults: A randomized controlled trial. International Journal of Nursing Studies, 2024, 152, 104701.	5.6	0
539	Small vessel cerebrovascular disease is associated with cognition in prospective Alzheimerâ€™s clinical trial participants. Alzheimer's Research and Therapy, 2024, 16, .	6.2	0
540	Investigating White Matter Neuroinflammation in Alzheimer Disease Using Diffusion-Based Neuroinflammation Imaging. Neurology, 2024, 102, .	1.1	1
542	Speech patterns during memory recall relates to early tau burden across adulthood. Alzheimer's and Dementia, 2024, 20, 2552-2563.	0.8	0
543	Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimerâ€™s Disease. Molecular Neurodegeneration, 2024, 19, .	10.8	0
544	Sex Differences in Conversion Risk from Mild Cognitive Impairment to Alzheimerâ€™s Disease: An Explainable Machine Learning Study with Random Survival Forests and SHAP. Brain Sciences, 2024, 14, 201.	2.3	0
546	The structuralâ€“functional-connectivity coupling of the aging brain. GeroScience, 0, , .	4.6	0
547	Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease. Alzheimer's and Dementia, 0, , .	0.8	0
548	Disease staging of Alzheimerâ€™s disease using a CSF-based biomarker model. Nature Aging, 0, , .	11.6	0